Interim Reports
Latest Reports
Interim Report 3 2023/24
This quarter set new records for PHI, achieving our highest-ever sales and advancing our strategic initiatives significantly. The strengthening of our partnership with Altium and the expanding reach of QPI technology highlights our leading position in the field. This quarter truly shows our continuous progress toward our core mission: making cell-based therapies accessible, affordable, and safe for all.
Learn more …
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
Learn more …
Interim Report 1 2023/24
During this past summer quarter, we made it our most prosperous Q1 quarter to date, characterized by sustained growth.
Learn more …
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Learn more …
Interim Report 3 2022/23
Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.
Learn more …
Interim Report 2 2022/23
The online sales and lead generation strategy continues to deliver. As a result, sales from August to October this year reached 2.7 KSEK — an increase of 50 % compared to any previous corresponding period.
Learn more …
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
Learn more …